May 14th 2020
This webinar is organised and funded by Lundbeck
Vortioxetine is indicated for the treatment of major depressive episodes in adults.
Lundbeck’s products will be discussed during this webinar.
Prescribing information and adverse event reporting will be available at the main event page.
The webinar will discuss the prevalence of emotional blunting in patients with Major Depressive Disorder (MDD), its impact on patients’ lives and the neurophysiological explanation for emotional blunting. Real-world observations from clinical practice will be discussed via a series of case studies exploring approaches to identifying and addressing the issue in clinical practice.